A solid phase sandwich immunoenzymmetric assay is described for the determination of apolipoprotein B in apolipoprotein CII-and/or CHI-containing lipoproteins (chylomicron remnants, VLDL, IDL). During a first incubation step the particles containing apolipoproteins CII and/or CIII are bound to antibodies against these components, while the antibodies are immobilised on microtitre plate wells. After washing, antiapolipoprotein B is added in a second incubation step. Finally peroxidase-labelled anti-sheep IgG reacts with the bound anti-apolipoprotein B, thus allowing the quantification of complexes containing both B and CII/ CIII apolipoproteins.
Introduction
1 1 -n · .1 · . ,*~ "ĉ hylomicrons as well as in their remnants (12 -16) . The total serum concentration of apolipoprotein B is Although an increase in VLDL concentration does a well known risk factor for premature coronary heart not appear to represent a primary risk factor for disease. LDL enriched in apolipoprotein B relative to coronary heart disease, some studies have revealed an lipids are known to be especially atherogenic (1 -11) . association between increased concentrations of this However, in hypertriglyceridaemic sera, up to 50% lipoprotein and premature development of atheroof total apolipoprotein B are present in VLDL and sclerosis (17 -19) . The special role played by VLDL in the development of atherosclerosis may lie in the ') Funding organisation: Ministerium für Wissenschaft, Foraltered composition of these particles in patients when schung und Technik Nordrhein-Westfalen, IV B 5-40001986 compared with healthy controls (20, 21) . Hence it is of interest to quantify the concentration of apolipoprotein B in VLDL. To date, the measurement of this analyte requires time-consuming analysis with ultracentrifugation or lengthy sample preparation (22, 23) . Due to these obstacles, epidemiological or larger clinical studies have not taken this important quantity into consideration.
We present here an immunoenzymmetric quantitation of apolipoprotein CII/CIH-apolipoprotein B which can be performed within one working day, without ultracentrifugation and pretreatment of samples. Furthermore, native lipoprotein particles are used, which eliminates disturbances due to artificial changes. This technique is based on the fact that VLDL are the only lipoproteins in human serum which contain C apolipoproteins as well as apolipoprotein B, with the exception of relatively small amounts of chylomicron remnants and IDL. In a first step, all apolipoprotein CII/CHI-containig lipoproteins are linked to the fixed phase. In the second step, the apolipoprotein B contained in these particles is quantified.
Materials and Methods

Samples
In this study we investigated a total of 258 subjects who belonged to the following groups:
(a) normal individuals: 90 male and 31 female subjects of the PROCAM study pool (24) showing normal lipid and lipoprotein patterns, and fasting glucose concentrations within the normal range (3.33 -6.05 mmol/1) (b) patients with coronary heart disease: 61 male and 18 female patients of the LVA Fachklinik Salzetal (Head: Prof. Dr. E. K hler) with coronary atherosclerosis as confirmed by coronary angiography (c) subjects with lipid metabolism disorders: 35 male and 23 female patients from the outpatient clinic of the Institute of Clinical Chemistry and Laboratory Medicine, University of M nster, presenting with various forms of dyslipidaemia.
Measurements were done on large series of frozen serum samples, which were frozen at -70 °C for a maximum of 6 months. Stability of the samples for at least 6 months had been ascertained previously in a comparative study of 30 samples.
Methods
Raising of antibodies and preparation for assay Apolipoproteins CII and CIII were isolated by preparative isoelectric focusing of VLDL apolipoproteins, which were obtained by ultracentrifugation and subsequent delipidation (25) . Anti-apolipoprotein CII and anti-apolipoprotein CIII antisera were raised in two New Zealand white rabbits by subcutaneous injection of l mg of the respective antigen in complete Freuntfs adjuvant, followed after six weeks with a booster injection of a 0.5 mg apolipoprotein in incomplete Freund*s adjuvant. Starting at the third week after boosting, 40ml blood was taken from the auricular artery once a week from each rabbit. The antisera were tested for monospecifity by Ouchterlony diffusion, two-dimensional electroimmunodiffusion, and Western blotting against isolated lipoproteins as well as purified apolipoproteins. In the immunoenzymmetric assay a mixture of equal amounts of chromatographically (DEAE-sepharose) purified IgG fractions (26) of anti-apolipoprotein CII and anti-apolipoprotein CIII antibodies was used for coating. For the detection step, sheep anti-apolipoprotein B antibodies (Boehringer Mannheim) and horseradish peroxidase-labelled anti-sheep IgG (Dako) were used. The anti-apolipoprotein C antibodies were stored at -20 °C, anti-apolipoprotein B antibodies and the enzyme conjugate at + 4 °C.
Lipid analysis
Total cholesterol and triacylglycerols were determined enzymatically with the SMAC autoanalyser (Technicon GmbH) as previously described (27) . HDL-cholesterol was measured following precipitation with phosphotungstic acid/MgC! 2 (28) using the COBAS Bio centrifugal analyser (Roche). LDL-cholesterol was calculated using the Friedewald formula (29).
Apolipoprotein analysis
Apolipoproteins AI and B were measured turbidimetrically, as previously described (30) . For the determination of apolipoprotein CII/CIH-apolipoprotein B, microtitre plates from Dynatech were selected, because specific binding of antibodies during coating was high and unspecific binding during the following incubation steps was low, compared with other microtitre plates (Costar, Flow, NUNC). No interlot variations were observed using three different lots of Dynatech plates. The microtitre plates were coated with the optimal concentration of 0.1 μg anti-apolipoprotein CII +0.1 μg anti-apolipoprotein CIII per well, which had been determined earlier in a dilution series using a checker board system. Coating was performed overnight in carbonate buffer (0.1 mol/1, pH 9.6), followed by washing 5 times with 0.15 mmol/1 NaCl containing 50 μΐ/ΐ Tween 20. A sample (100 μΐ) containing serum and phosphate buffered saline (0.1 mol/1, pH 7.4) in a ratio 1 : 100 or 1 :200 was placed in each well of the microtitre plate and incubated for two hours. After washing 5 times with phosphate buffered saline, 1 μg anti-apolipoprotein B antibody (Boehringer Mannheim), diluted 1 : 20000 in phosphate buffered saline was added to each well and incubated for two hours. Subsequently the plates were again washed 5 times with phosphate buffered saline and then incubated for two hours with peroxidase-labelled anti-sheep antibody diluted 1 : 1000 in phosphate buffered saline. All incubation steps were carried out at room temperature. After another washing step, 100 μΐ o-phenylenediamine/H 2 O 2 were added as substrate. The colour reaction was stopped after half an hour by addition of 100 μΐ 1 mol/1 H 2 SO 4 . A Dynatech MR 600 microtitre reader coupled to a computer was used for data reduction.
Intra-and inter-assay variation
The intra-assay variations amounted to 7.5% and 5.5% (n = 20) and the inter-assay variations were 10.4% and 6.7% (n = 30) at concentrations of 0.08 g/1 and 0.16 g/1 apolipoprotein CII/CIII-B, respectively. The linear range extended from 0.01 g/1 to 0.5 g/1. The sensitivity of the assay was 10 μg/l apolipoprotein CII/CIII-B. Disturbances by extremely high concentrations of triacylglycerols (> 6.8 mmol/1) or cholesterol (> 10.4 mmol/1) were not observed.
Calibration
The assays were calibrated with a dilution series of a normolipaemic pool serum. After determination of total apolipoprotein B using turbidimetry, all CII/CIII-containing lipoproteins were removed by antibody-mediated fixed phase immune ad- 
Results
Distributions and and correlations
Control group
Coronary patients
The distribution of lipid quantities measured in the collective of male and female patients with coronary heart disease is shown in 
Dyslipidaemic patients
In table 5 the statistical description of a group of dyslipidaemic patients is presented. In men we observed a negative correlation between apolipoprotein CII/CIII-B and age, in women a positive correlation between apolipoprotein CII/CIII-B and the concentrations of cholesterol, triacylglycerols, LDL-cholesterol, and apolipoprotein B (tab. 6).
Comparison of groups Table 7 shows a comparison of the results obtained in the 3 different male collectives. Of special interest are the significantly lower HDL-cholesterol and apolipoprotein AI concentrations in the group of coronary heart disease patients compared with the control group and the group of hyperlipidaemic patients. Furthermore, the coronary heart disease patients group 
Discussion
Methods previously available for the quantitation of apolipoprotein B in different lipoproteins were disadvantageous, because their laborious sample preparation, precipitation, or ultracentrifugation precluded their use for the investigation of large numbers of samples. The immunoenzymmetric assay introduced here allows for the quantitation of apolipoprotein B in native particles from serum and permits the economic study of larger collectives. Furthermore, measurements with the immunoenzymmetric assay result in faster and more accurate results than the radial immunodiffusion method, which has been described for the determination of VLDL apolipoprotein B (32) . Another important advantage of this new method is that the measured analyte is defined much more accurately by its apolipoprotein composition than lipoproteins obtained by ultracentrifugation or precipitation with polyanions.
Calibration is difficult for both radial immunodiffusion and immunoenzymmetric assays. Radial immunodiffusion is calibrated with an apolipoprotein B value obtained by determination of tetramethyl ureainsoluble proteins in the supernatant after polyvinylsulphate precipitation (32) . This procedure requires several steps and therefore easily leads to inaccuracies. The calibration of the immunoenzymmetric assay test only requires the immunoadsorption, and no further preparative or dilution procedures.
It is important to note that the analytes, VLDL apolipoprotein B and apolipoprotein CII/CIII-B, are not identical. VLDL apolipoprotein B concentrations in a control group amount to about 5% of the total apolipoprotein B, whereas apolipoprotein CII/CIII-B amounts to about 20%. This discrepancy is probably caused by co-measurement of chylomicron remnants and IDL in the described immunoenzymmetric test. The atherogenic properties of these lipoproteins are as yet not fully understood.
The possible clinical implication of apolipoprotein CII/CIII-B measurement is highlighted by our observation that apolipoprotein CII/CIII-B concentrations negatively correlate with HDL-cholesterol in male coronary heart disease patients and are significantly higher in coronary heart disease patients than in normal controls. This may reflect a disturbed lipid and protein exchange between VLDL and HDL in coronary heart disease patients, which results in an accumulation of apolipoprotein B-containing VLDL, and hence in a pathogenetic influence on the atherosclerotic process. In male patients with low HDL-cholesterol concentrations, it now appears feasible to use the apolipoprotein CII/CIII-B concentration as an additional value for a more accurate individual risk evaluation.
The results reported here are statistically significant, but their potential clinical importance must be established by larger control studies on an appropriate collective.
